C000272877 Fees and Costs — CapForce IBD Breakout Opportunities ETF
Data updated: 2026-09-21
The net expense ratio is 0.80%: a 0.70% management fee plus 0.30% other expenses, less a 0.20% fee waiver. There are no sales loads or redemption fees. Portfolio turnover was 1668%.
C000272877 Fees and Expenses
Annual operating expenses and sales charges of C000272877. Prospectus, as of October 31, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.70% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.30% |
| Gross expense ratio | 1.00% |
| Fee waiver | −0.20% |
| Net expense ratio | 0.80% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
C000272877 Costs Over Time
On $10,000 invested in C000272877, assuming 5% a year before costs, total costs come to $502 over 5 years, cutting the return by 0.84% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.80%) | $84 | $263 | $456 |
| Lost growth on money paid in costs | $0 | $13 | $46 |
| Total costs | $84 | $276 | $502 |
| Value after costs | $10,416 | $11,301 | $12,260 |
| Impact on return, per year | 0.84% | 0.84% | 0.84% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.